文献速递临床试验与 GCP新药、器械与细胞基因治疗研发

氨甲环酸与脑膜中动脉栓塞作为慢性硬膜下血肿术后减少复发率的辅助治疗方案比较(TABASCO):一项随机对照试验

Tranexamic acid vs. embolization of the meningeal artery as an adjunctive therapeutic regime to reduce the recurrence rate after surgical relief of chronic subdural hematomas (TABASCO)-a randomized controlled trial.
PubMed 文献 · Trials · 2025-06-14

TABASCO为前瞻性、随机、双臂、多中心临床试验,拟比较慢性硬膜下血肿术后氨甲环酸药物治疗(试验组)与脑膜中动脉栓塞(对照组)在术后血肿体积减少及再次手术需求上是否等效。计划纳入276例(每组138例),主要终点为术后3个月血肿体积下降,关键次要终点为再次手术率。

要点

  • 研究比较慢性硬膜下血肿术后氨甲环酸药物辅助与脑膜中动脉栓塞两种策略的疗效与安全性。
  • 主要终点为术后3个月手术侧血肿体积的定量下降及其时间过程。
  • 样本量基于再出血及再次手术风险差异8%、把握度80%估算,计划纳入276例(每组138例)。

核心结论

  • TABASCO研究将提供临床证据,判断脑膜中动脉栓塞联合手术与氨甲环酸术后药物辅助治疗在血肿体积减少、再次手术率和操作安全性方面是否可比。

研究设计与样本

  • TABASCO为前瞻性、随机、双臂、多中心临床试验,按1:1随机分为试验组(术后氨甲环酸药物辅助治疗)与对照组(术后脑膜中动脉栓塞)。
  • 纳入标准为18岁以上、首次因慢性硬膜下血肿接受手术且术后不超过24小时的患者,计划纳入276例(每组138例)。
  • 样本量估算基于再出血及再次手术的风险差异8%、把握度80%。

主要发现

  • 原文未报告研究结果(方案描述性文章)。

关键数值与推荐

  • 主要终点为术后3个月研究期内手术侧血肿体积的定量下降及其时间过程。
  • 次要终点为术后3个月内辅助治疗对必要再次手术率的影响程度。
  • 三级终点为术后总随访3个月时不同治疗组患者的神经功能结局及辅助操作的并发症率。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Chronic subdural hematoma is a persistent, bloody to serous fluid retention in the subdural space between the dura mater and arachnoid mater, usually caused by an initial trauma, and is one of the most common traumatic intracranial hemorrhages in western industrialized nations. In the event of a compressive effect on the brain, the hematoma is usually relieved by means of a burr hole trephination. In view of the high postoperative recurrence rate, conservative treatment methods have been investigated both as a competitor to surgery alone in cases where the indication for surgery is debatable and as a supportive therapy for surgical hematoma relief. Studies on embolization of the middle meningeal artery during surgery as well as studies on postoperative drug therapy using tranexamic acid have shown the most promise. However, there is currently a lack of studies that randomly compare the effectiveness of these two perioperative treatment strategies regarding to their efficacy in avoiding revision surgery and the safety of the respective procedure. METHODS: TABASCO is a prospective, randomized, two-arm, multicenter, clinical trial designed to determine whether postoperative treatment of chronic subdural hematomas using adjuvant drug therapy with tranexamic acid (test group) is equivalent to postoperative embolization of the arteria meningea media (control group) in terms of postoperative volume reduction of the hematoma and the need for revision surgery of CSDH. Patients over 18 years of age who have undergone surgery for CSDH for the first time no more than 24 h before inclusion in the study will be randomized 1:1 to the test group or control group. The primary endpoint is the postoperative volume decrease of a primarily surgically relieved CSDH quantitatively and regarding to the time course on the affected side in a study period of 3 months postoperatively. The secondary endpoint of this study is to investigate the extent to which the rate of necessary revision surgery can be influenced by the adjuvant therapy procedures over the course of 3 months. The tertiary endpoint is the neurological outcome of the patients included in the study and assigned to the different treatment arms after a total follow-up period of 3 months as well as the complication rate of the adjuvant procedures used. Assuming a risk difference of 8% for rebleeding and surgical revision, with an applied power of 80%, 276 patients (138 per group) will be included in this study. DISCUSSION: The TABASCO study will provide clinical evidence as to whether embolization of the middle meningeal artery in addition to surgery is comparable to postoperative drug therapy using tranexamic acid as an adjuvant treatment method for operated chronic subdural hematomas in terms of hematoma volume reduction, revision rate and safety of the procedures. TRIAL REGISTRATION: German Clinical Trials Registry (Deutsches Register Klinischer Studien (DRKS)) DRKS00033515. Registered on 05 Feb 2024.

来源:Trials,查看原文。版权归原作者所有。

引用

  1. Scheer M, Beuchel V, Mauer UM, et al. Tranexamic acid vs. embolization of the meningeal artery as an adjunctive therapeutic regime to reduce the recurrence rate after surgical relief of chronic subdural hematomas (TABASCO)-a randomized controlled trial. Trials. 2025. PMID: 40517222. doi:10.1186/s13063-025-08888-6

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。